Ascletis Announces Oral and Poster Presentations on ASC47, an Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate for Obesity at the 32nd European Congress on Obesity

Core Insights - Ascletis Pharma Inc. is presenting preliminary studies of ASC47, a weight loss drug candidate, at the 32nd European Congress On Obesity (ECO 2025) in Malaga, Spain [1] Group 1: Presentation Details - The oral presentation titled "ASC47, An Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate For Obesity, Demonstrated Significant Weight Loss And Preserved Muscle In DIO Mice" will take place on May 13, 2025 [2] - A guided poster presentation titled "ASC47, a Muscle-Preserving Weight Loss Drug Candidate in Healthy Participants: A First-in-human Single Ascending Dose Study" is also scheduled for May 13, 2025 [3] Group 2: About ASC47 - ASC47 is an adipose-targeted, ultra-long-acting subcutaneously injected thyroid hormone receptor beta selective small molecule agonist developed in-house at Ascletis [3] - The drug shows dose-dependent high drug concentrations in adipose tissue and has completed Phase Ib single subcutaneous injection studies in Australia [3] - The U.S. FDA has cleared the Investigational New Drug (IND) application for ASC47 in combination with semaglutide for obesity treatment [3] Group 3: About Ascletis Pharma Inc. - Ascletis is an innovative R&D driven biotech company listed on the Hong Kong Stock Exchange, focusing on metabolic diseases [5] - The company covers the entire value chain from discovery and development to GMP manufacturing and has multiple clinical stage drug candidates in its metabolic disease pipeline [5] Group 4: About European Congress on Obesity - The European Congress on Obesity (ECO) is an annual scientific congress established by the European Association for the Study of Obesity (EASO), which includes professionals from various areas of obesity research, prevention, and management [4]